Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 91,152,928
  • Shares Outstanding, K 780,820
  • Annual Sales, $ 11,229 M
  • Annual Income, $ 1,999 M
  • 36-Month Beta 1.76
  • Price/Sales 8.19
  • Price/Cash Flow 19.55
  • Price/Book 12.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.63 +2.77%
on 05/22/17
124.98 -6.56%
on 04/27/17
-8.42 (-6.73%)
since 04/26/17
3-Month
113.63 +2.77%
on 05/22/17
127.64 -8.51%
on 03/17/17
-1.45 (-1.23%)
since 02/24/17
52-Week
94.42 +23.68%
on 06/27/16
127.64 -8.51%
on 03/17/17
+11.00 (+10.40%)
since 05/26/16

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

CELG : 116.78 (+0.03%)
REGN : 455.17 (-0.12%)
AMGN : 155.01 (-0.27%)
Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with Relapsing Multiple Sclerosis

Upcoming AWS Coverage on Regeneron Pharmaceuticals Post-Earnings Results

CELG : 116.78 (+0.03%)
REGN : 455.17 (-0.12%)
CELGZ : 1.13 (-5.83%)
Celgene (CELG) Approaches New Downside Target of $115.87

Shares of Celgene (NASDAQ:CELG) opened today below their pivot of $117.41 and have already reached the first level of support at $116.40. Investors may be interested in a cross of the next downside pivot...

CELG : 116.78 (+0.03%)
Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis

--Safety and tolerability consistent with prior phase II and III studies

CELG : 116.78 (+0.03%)
CELGZ : 1.13 (-5.83%)
Celgene Falls 1.62% on Heavy Volume: Watch For Potential Rebound

Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $117.01 to a high of $118.80. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $118.55...

CELG : 116.78 (+0.03%)
After Yesterday's Decline of 1.62%, Celgene Offers Investors Better Value

Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $117.01 to a high of $118.80. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $118.55...

CELG : 116.78 (+0.03%)
Celgene's (CELG) Revlimid Looks Solid on Label Expansion

Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.

CELG : 116.78 (+0.03%)
VVUS : 1.13 (+0.89%)
ABBV : 66.06 (-0.39%)
AMGN : 155.01 (-0.27%)
Today's Research Reports on Stocks to Watch: Allergan and Celgene

NEW YORK, NY / ACCESSWIRE / May 11, 2017 / Botox maker Allergan suffered a loss on Wednesday, the day after the multi-national pharmaceutical company released its first quarter earnings that beat estimates....

CELG : 116.78 (+0.03%)
AGN : 223.12 (-0.55%)
CELGZ : 1.13 (-5.83%)
Western Digital, Mattel, Celgene and Acceleron Pharma highlighted as Zacks Bull and Bear of the Day

Western Digital, Mattel, Celgene and Acceleron Pharma highlighted as Zacks Bull and Bear of the Day

MAT : 22.53 (+1.58%)
CELG : 116.78 (+0.03%)
WDC : 90.01 (+0.83%)
XLRN : 25.25 (-4.54%)
Today's Research Reports on Trending Tickers: Celgene and Kite Pharma

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Celgene takes a hit for its partner Acceleron after the company posted first quarter earnings results that depressed investors. Kite Pharma on the other hand...

CELG : 116.78 (+0.03%)
XLRN : 25.25 (-4.54%)
KITE : 73.11 (-2.40%)
CELGZ : 1.13 (-5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Business Summary

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

See More

Support & Resistance

2nd Resistance Point 117.60
1st Resistance Point 117.19
Last Price 116.78
1st Support Level 116.36
2nd Support Level 115.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.